Nicotine reduces the incidence of type I diabetes in mice

J. G. Mabley, P. Pacher, G. J. Southan, A. L. Salzman, Csaba Szabo

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Nicotine has been previously shown to have immunosuppressive actions. Type I diabetes is an autoimmune disease resulting from the specific destruction of the insulin-producing pancreatic β-cells. Thus, we hypothesized that nicotine may exert protective effects against type I diabetes. The multiple low-dose streptozotocin (MLDS)-induced model and spontaneous nonobese diabetic (NOD) mouse model of type I diabetes were used to assess whether nicotine could prevent this autoimmune disease. Blood glucose levels, diabetes incidence, pancreas insulin content, and cytokine levels were measured in both models of diabetes, both to asses the level of protection exerted by nicotine and to further investigate its mechanism of action. Nicotine treatment reduced the hyperglycemia and incidence of disease in both the MLDS and NOD mouse models of diabetes. Nicotine also protected against the diabetes-induced decrease in pancreatic insulin content observed in both animal models. The pancreatic levels of the Th1 cytokines interleukin (IL)-12, IL-1, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were increased in both MLDS-induced and spontaneous NOD diabetes, an effect prevented by nicotine treatment. Nicotine treatment increased the pancreatic levels of the Th2 cytokines IL-4 and IL-10. Nicotine treatment reduces the incidence of type 1 diabetes in two animal models by changing the profile of pancreatic cytokine expression from Th1 to Th2.

Original languageEnglish (US)
Pages (from-to)876-881
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume300
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Nicotine
Incidence
Streptozocin
Cytokines
Inbred NOD Mouse
Insulin
Autoimmune Diseases
Animal Models
Equidae
Interleukin-12
Immunosuppressive Agents
Interleukin-1
Interleukin-4
Hyperglycemia
Interleukin-10
Interferons
Blood Glucose
Pancreas
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nicotine reduces the incidence of type I diabetes in mice. / Mabley, J. G.; Pacher, P.; Southan, G. J.; Salzman, A. L.; Szabo, Csaba.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 300, No. 3, 2002, p. 876-881.

Research output: Contribution to journalArticle

Mabley, J. G. ; Pacher, P. ; Southan, G. J. ; Salzman, A. L. ; Szabo, Csaba. / Nicotine reduces the incidence of type I diabetes in mice. In: Journal of Pharmacology and Experimental Therapeutics. 2002 ; Vol. 300, No. 3. pp. 876-881.
@article{acdfc61a8f764982831ea8bd4358c744,
title = "Nicotine reduces the incidence of type I diabetes in mice",
abstract = "Nicotine has been previously shown to have immunosuppressive actions. Type I diabetes is an autoimmune disease resulting from the specific destruction of the insulin-producing pancreatic β-cells. Thus, we hypothesized that nicotine may exert protective effects against type I diabetes. The multiple low-dose streptozotocin (MLDS)-induced model and spontaneous nonobese diabetic (NOD) mouse model of type I diabetes were used to assess whether nicotine could prevent this autoimmune disease. Blood glucose levels, diabetes incidence, pancreas insulin content, and cytokine levels were measured in both models of diabetes, both to asses the level of protection exerted by nicotine and to further investigate its mechanism of action. Nicotine treatment reduced the hyperglycemia and incidence of disease in both the MLDS and NOD mouse models of diabetes. Nicotine also protected against the diabetes-induced decrease in pancreatic insulin content observed in both animal models. The pancreatic levels of the Th1 cytokines interleukin (IL)-12, IL-1, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were increased in both MLDS-induced and spontaneous NOD diabetes, an effect prevented by nicotine treatment. Nicotine treatment increased the pancreatic levels of the Th2 cytokines IL-4 and IL-10. Nicotine treatment reduces the incidence of type 1 diabetes in two animal models by changing the profile of pancreatic cytokine expression from Th1 to Th2.",
author = "Mabley, {J. G.} and P. Pacher and Southan, {G. J.} and Salzman, {A. L.} and Csaba Szabo",
year = "2002",
doi = "10.1124/jpet.300.3.876",
language = "English (US)",
volume = "300",
pages = "876--881",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Nicotine reduces the incidence of type I diabetes in mice

AU - Mabley, J. G.

AU - Pacher, P.

AU - Southan, G. J.

AU - Salzman, A. L.

AU - Szabo, Csaba

PY - 2002

Y1 - 2002

N2 - Nicotine has been previously shown to have immunosuppressive actions. Type I diabetes is an autoimmune disease resulting from the specific destruction of the insulin-producing pancreatic β-cells. Thus, we hypothesized that nicotine may exert protective effects against type I diabetes. The multiple low-dose streptozotocin (MLDS)-induced model and spontaneous nonobese diabetic (NOD) mouse model of type I diabetes were used to assess whether nicotine could prevent this autoimmune disease. Blood glucose levels, diabetes incidence, pancreas insulin content, and cytokine levels were measured in both models of diabetes, both to asses the level of protection exerted by nicotine and to further investigate its mechanism of action. Nicotine treatment reduced the hyperglycemia and incidence of disease in both the MLDS and NOD mouse models of diabetes. Nicotine also protected against the diabetes-induced decrease in pancreatic insulin content observed in both animal models. The pancreatic levels of the Th1 cytokines interleukin (IL)-12, IL-1, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were increased in both MLDS-induced and spontaneous NOD diabetes, an effect prevented by nicotine treatment. Nicotine treatment increased the pancreatic levels of the Th2 cytokines IL-4 and IL-10. Nicotine treatment reduces the incidence of type 1 diabetes in two animal models by changing the profile of pancreatic cytokine expression from Th1 to Th2.

AB - Nicotine has been previously shown to have immunosuppressive actions. Type I diabetes is an autoimmune disease resulting from the specific destruction of the insulin-producing pancreatic β-cells. Thus, we hypothesized that nicotine may exert protective effects against type I diabetes. The multiple low-dose streptozotocin (MLDS)-induced model and spontaneous nonobese diabetic (NOD) mouse model of type I diabetes were used to assess whether nicotine could prevent this autoimmune disease. Blood glucose levels, diabetes incidence, pancreas insulin content, and cytokine levels were measured in both models of diabetes, both to asses the level of protection exerted by nicotine and to further investigate its mechanism of action. Nicotine treatment reduced the hyperglycemia and incidence of disease in both the MLDS and NOD mouse models of diabetes. Nicotine also protected against the diabetes-induced decrease in pancreatic insulin content observed in both animal models. The pancreatic levels of the Th1 cytokines interleukin (IL)-12, IL-1, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were increased in both MLDS-induced and spontaneous NOD diabetes, an effect prevented by nicotine treatment. Nicotine treatment increased the pancreatic levels of the Th2 cytokines IL-4 and IL-10. Nicotine treatment reduces the incidence of type 1 diabetes in two animal models by changing the profile of pancreatic cytokine expression from Th1 to Th2.

UR - http://www.scopus.com/inward/record.url?scp=0036179356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036179356&partnerID=8YFLogxK

U2 - 10.1124/jpet.300.3.876

DO - 10.1124/jpet.300.3.876

M3 - Article

VL - 300

SP - 876

EP - 881

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -